Published in ORL J Otorhinolaryngol Relat Spec on March 24, 2010
Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76
DNA methylation changes associated with risk factors in tumors of the upper aerodigestive tract. Epigenetics (2012) 0.97
Role of DNA methylation in head and neck cancer. Clin Epigenetics (2011) 0.94
Genome stability pathways in head and neck cancers. Int J Genomics (2013) 0.79
RAD51C--a new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC). Oral Oncol (2013) 0.78
Implications of systemic dysfunction for the etiology of malignancy. Gene Regul Syst Bio (2013) 0.78
Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling. Clin Cancer Res (2015) 0.77
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A (1996) 29.54
The role of DNA methylation in mammalian epigenetics. Science (2001) 9.26
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
A genetic and clinical study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum. Am J Hum Genet (1951) 6.57
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med (1969) 6.54
Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res (1996) 4.89
The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet (2001) 4.07
Cancer incidence in persons with Fanconi anemia. Blood (2002) 4.05
Dyskeratosis congenita in all its forms. Br J Haematol (2000) 3.89
Impaired control of IRES-mediated translation in X-linked dyskeratosis congenita. Science (2006) 3.37
Cancer in Fanconi anemia, 1927-2001. Cancer (2003) 3.31
Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood (2005) 3.30
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18
BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci U S A (2002) 2.62
Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br J Haematol (1998) 2.43
Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res (2000) 1.91
Fanconi anemia: adult head and neck cancer and hematopoietic mosaicism. Arch Otolaryngol Head Neck Surg (2005) 1.91
Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene (2004) 1.82
Dyskeratosis congenita: clinical features and genetic aspects. Report of a family and review of the literature. J Med Genet (1975) 1.77
Genetic basis of Fanconi anemia. Curr Opin Hematol (2003) 1.76
Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res (2003) 1.65
Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol (2006) 1.61
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53
The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle (2003) 1.23
Dyskeratosis congenita: a disorder of defective telomere maintenance? Int J Hematol (2005) 1.22
The Fanconi road to cancer. Genes Dev (2003) 1.21
Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization. Laryngoscope (2006) 1.08
Molecular pathology of head-and-neck cancer. Int J Cancer (2004) 1.05
Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res (2003) 1.00
Dyskeratosis congenita with pigmentation, dystrophia unguium, and leucokeratosis oris; review of the known cases reported to date and discussion of the disease from various aspects. AMA Arch Derm (1955) 0.95
Molecular pathogenesis of Fanconi anemia. Int J Hematol (2005) 0.94
Multiple squamous-cell carcinomas in Fanconi's anemia. Cancer (1982) 0.91
Oral carcinoma in a young man: a case of dyskeratosis congenita. J Eur Acad Dermatol Venereol (2000) 0.91
THE ASSOCIATION OF DYSKERATOSIS CONGENITA AND FANCONI'S ANAEMIA. Med J Aust (1965) 0.90
Tongue cancer as a complication of dyskeratosis congenita in a woman. Am J Otolaryngol (2000) 0.90
Dyskeratosis congenita. Br J Oral Surg (1971) 0.88
Dyskeratosis congenita with pigmentation, dystrophia unguium, and leukoplakia oris; a follow-up report of two brothers. AMA Arch Derm (1958) 0.85
Dyskeratosis congenita with macular cutaneous amyloid deposits. Arch Dermatol (1984) 0.84
Dyskeratosis congenita vs. chronic graft versus host disease: report of a case and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2004) 0.83
Oral squamous cell carcinoma in a case of dyskeratosis congenita. Ann Dent (1994) 0.83
Dyskeratosis congenita with associated periodontal disease. Oral Surg Oral Med Oral Pathol (1974) 0.80
Head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg (2005) 0.78
[Dyskeratosis congenita in a 40-year-old patient]. Hautarzt (2006) 0.77
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer (2005) 3.27
Alcohol consumption and expenditures for underage drinking and adult excessive drinking. JAMA (2003) 2.59
MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer (2008) 2.56
Impact of pharyngeal closure technique on fistula after salvage laryngectomy. JAMA Otolaryngol Head Neck Surg (2013) 2.37
Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem (2008) 2.07
DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer (2007) 1.97
Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res (2002) 1.97
Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon. Head Neck (2008) 1.97
Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res (2004) 1.74
Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol (2003) 1.70
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68
Consensus statement on the classification and terminology of neck dissection. Arch Otolaryngol Head Neck Surg (2008) 1.68
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res (Phila) (2010) 1.68
Accuracy of intraoperative gross examination of surgical margin status in women undergoing partial mastectomy for breast malignancy. Am Surg (2005) 1.65
Mitochondrial mutations are a late event in the progression of head and neck squamous cell cancer. Clin Cancer Res (2007) 1.62
Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.62
Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol (2006) 1.61
The molecular biology of mucosal field cancerization of the head and neck. Crit Rev Oral Biol Med (2003) 1.58
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer (2006) 1.56
Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. Int J Cancer (2010) 1.53
Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res (2002) 1.53
Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One (2009) 1.45
DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Res (2005) 1.44
Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One (2012) 1.43
Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions. Clin Cancer Res (2004) 1.37
The role of human papillomavirus in oral carcinogenesis. Crit Rev Oral Biol Med (2004) 1.31
Presence of HPV DNA in convalescent salivary rinses is an adverse prognostic marker in head and neck squamous cell carcinoma. Oral Oncol (2008) 1.29
TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res (2010) 1.27
Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res (2010) 1.26
KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. Int J Cancer (2010) 1.26
Mitochondrial mutations contribute to HIF1alpha accumulation via increased reactive oxygen species and up-regulated pyruvate dehydrogenease kinase 2 in head and neck squamous cell carcinoma. Clin Cancer Res (2009) 1.24
Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Lett (2008) 1.23
Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. Cancer Res (2006) 1.22
Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res (2003) 1.20
Value of chest CT in the diagnosis and management of tracheobronchial foreign bodies. Pediatr Int (2011) 1.16
Activation of the NOTCH pathway in head and neck cancer. Cancer Res (2013) 1.15
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS One (2009) 1.14
An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin Cancer Res (2011) 1.13
Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS One (2011) 1.12
p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol (2010) 1.10
Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. Clin Cancer Res (2011) 1.09
A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer (2011) 1.08
Mitochondrial DNA mutations in preneoplastic lesions of the gastrointestinal tract: a biomarker for the early detection of cancer. Mol Cancer (2006) 1.08
A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol (2011) 1.06
Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res (2008) 1.05
Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. Biochem Biophys Res Commun (2008) 1.05
Molecular pathology of head-and-neck cancer. Int J Cancer (2004) 1.05
Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance. Clin Cancer Res (2011) 1.04
Intraoperative molecular margin analysis in head and neck cancer. Arch Otolaryngol Head Neck Surg (2004) 1.04
Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer. Expert Opin Med Diagn (2010) 1.03
Serum protein MALDI profiling to distinguish upper aerodigestive tract cancer patients from control subjects. J Natl Cancer Inst (2003) 1.03
Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res (Phila) (2010) 1.03
The gastrointestinal manifestations of telomere-mediated disease. Aging Cell (2013) 1.00
Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer (2006) 1.00
Recurrence patterns and management of oral cavity premalignant lesions. Oral Oncol (2013) 1.00
EDNRB and DCC salivary rinse hypermethylation has a similar performance as expert clinical examination in discrimination of oral cancer/dysplasia versus benign lesions. Clin Cancer Res (2013) 0.99
DCC promoter hypermethylation in esophageal squamous cell carcinoma. Int J Cancer (2008) 0.98
Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer. Clin Cancer Res (2012) 0.97
Applying the molecular biology and epigenetics of head and neck cancer in everyday clinical practice. Oral Oncol (2008) 0.97
Molecular techniques and genetic alterations in head and neck cancer. Oral Oncol (2008) 0.96
Suprabasin is hypomethylated and associated with metastasis in salivary adenoid cystic carcinoma. PLoS One (2012) 0.96
Vitamin E succinate induces ceramide-mediated apoptosis in head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res (2008) 0.96
Decreased mitochondrial DNA content in posttreatment salivary rinses from head and neck cancer patients. Clin Cancer Res (2006) 0.96
Mitochondrial DNA mutation in normal margins and tumors of recurrent head and neck squamous cell carcinoma patients. Cancer Prev Res (Phila) (2010) 0.95
Estimate of the commercial value of underage drinking and adult abusive and dependent drinking to the alcohol industry. Arch Pediatr Adolesc Med (2006) 0.95
Quantitative methylation profiles for multiple tumor suppressor gene promoters in salivary gland tumors. PLoS One (2010) 0.95
The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins. Clin Cancer Res (2009) 0.95
Microsurgical salvage of the intractable oral vestibule. Plast Reconstr Surg (2009) 0.94
The role of pre-operative CT-guided FNAB for parapharyngeal space tumors. Otolaryngol Head Neck Surg (2007) 0.94
Cigarette smoke induces promoter methylation of single-stranded DNA-binding protein 2 in human esophageal squamous cell carcinoma. Int J Cancer (2011) 0.93
BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin Cancer Res (2011) 0.93
Promoter hypermethylation in Indian primary oral squamous cell carcinoma. Int J Cancer (2010) 0.92
ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer. Clin Cancer Res (2008) 0.91
Use of single nucleotide polymorphism arrays to identify a novel region of loss on chromosome 6q in squamous cell carcinomas of the oral cavity. Head Neck (2004) 0.91
Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol Cancer Ther (2012) 0.90
Neck management in patients undergoing postradiotherapy salvage laryngeal surgery for recurrent/persistent laryngeal cancer. Laryngoscope (2006) 0.90
Real-time gap ligase chain reaction: a rapid semiquantitative assay for detecting p53 mutation at low levels in surgical margins and lymph nodes from resected lung and head and neck tumors. Clin Cancer Res (2004) 0.90
Transoral robotic surgery experience in 44 cases. J Laparoendosc Adv Surg Tech A (2013) 0.89
Progression of microsatellite instability from premalignant lesions to tumors of the head and neck. Int J Cancer (2002) 0.89
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. Head Neck (2011) 0.89
Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Invest (2011) 0.89
Evaluation of MYB promoter methylation in salivary adenoid cystic carcinoma. Oral Oncol (2011) 0.89
Analysis of radiographically confirmed blunt-mechanism facial fractures. J Craniofac Surg (2014) 0.88
Death-associated protein kinase promoter hypermethylation in normal human lymphocytes. Cancer Res (2003) 0.88
Mitochondrial DNA alterations in thyroid cancer. J Surg Oncol (2003) 0.88